New treatment for longevity targeting molecular causes of ageing

[{"selector":"#anim-58c7413e-93b0-4936-bb59-b72665caa96e","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c449a6ea-e379-4a1e-9762-e5cd6fff13aa","keyframes":{"transform":["translate3d(0px, 100.04146%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Kristen Fortney, CEO and co-founder of BioAge, has raised $127 million to develop a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging.

[{"selector":"#anim-71910a36-ae45-44f5-92ed-5b5a6d4745e6","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-90f93795-9fad-4606-8f67-e36a962825d5","keyframes":{"transform":["translate3d(0px, -100.05514%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] The company aims to use artificial intelligence to transform longevity science R&D through AI-discovered biomarkers and predictive analytics to tackle the most fundamental problems of age.

[{"selector":"#anim-53d4cd73-b471-4f34-914d-f6b2930bac2b","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e6fc959d-3fed-445b-9d70-32a4cdbccef0","keyframes":{"transform":["translate3d(0px, -100.05514%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] By pinpointing the molecular differences that predict healthy versus unhealthy aging, BioAge is looking for the pathways that distinguish the most successful agers.

The proteins that play key roles in these pathways become their drug targets.

[{"selector":"#anim-fb8e4ef3-17cc-46f6-9469-2b3225547c20","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-10d336ca-d8e0-47a5-a09f-1d960de92d4e","keyframes":{"transform":["translate3d(0px, 100.04146%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

[{"selector":"#anim-61860e38-9d01-4c36-8d4d-fdc2126c2764","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-36b848dd-152c-470d-9dbc-3a2fe8656b60","keyframes":{"transform":["translate3d(0px, -100.05514%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Fortney believes that targeting ageing will enable disease to be treated in entirely new ways, and that BioAge's human data first approach is unique in that it can discover many different ageing mechanisms, rather than being limited to a handful of targets chosen in advance.